A newborn with unresectable kaposiform hemangioendothelioma associated with Kasabach Merritt phenomenon, unresponsive to vincristine and prednisone, received second-line treatment with propranolol at a dose of 2 mg/kg/day, starting at 2 months of life and continued for 13 months. There was only slight reduction in tumor mass, but measurement of propranolol levels showed extremely low plasma concentrations. The propranolol dose was progressively increased to 3.5 mg/kg/day, leading to a substantial increase in plasma levels associated with clinically relevant tumor reduction. This case highlights the importance of relating propranolol dose to its plasma concentration before considering the treatment ineffective for this vascular tumor.

Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol / Filippi, Luca; Tamburini, Angela; Berti, Elettra; Perrone, Anna; Defilippi, Claudio; Favre, Claudio; Calvani, Maura; Della Bona, Maria Luisa; la Marca, Giancarlo; Donzelli, Gianpaolo. - In: PEDIATRIC BLOOD & CANCER. - ISSN 1545-5009. - STAMPA. - 63:(2016), pp. 1290-1292. [10.1002/pbc.25979]

Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol

FILIPPI, LUCA;BERTI, ELETTRA;CALVANI, MAURA;LA MARCA, GIANCARLO;DONZELLI, GIAN PAOLO
2016

Abstract

A newborn with unresectable kaposiform hemangioendothelioma associated with Kasabach Merritt phenomenon, unresponsive to vincristine and prednisone, received second-line treatment with propranolol at a dose of 2 mg/kg/day, starting at 2 months of life and continued for 13 months. There was only slight reduction in tumor mass, but measurement of propranolol levels showed extremely low plasma concentrations. The propranolol dose was progressively increased to 3.5 mg/kg/day, leading to a substantial increase in plasma levels associated with clinically relevant tumor reduction. This case highlights the importance of relating propranolol dose to its plasma concentration before considering the treatment ineffective for this vascular tumor.
2016
63
1290
1292
Filippi, Luca; Tamburini, Angela; Berti, Elettra; Perrone, Anna; Defilippi, Claudio; Favre, Claudio; Calvani, Maura; Della Bona, Maria Luisa; la Marca...espandi
File in questo prodotto:
File Dimensione Formato  
2016-Ped Blood Cancer.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 224.03 kB
Formato Adobe PDF
224.03 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1053786
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact